Considering the process of interaction between inflammatory factors and various immune infiltrating components in BC (88, 89), the expression of NLRP3 inflammasome and inflammatory factors in BC epithelial cells and innate immune cells and so on (90), it is highly preferred to select inhibitors that directly target the NLRP3 protein to boost the effectiveness of chemotherapy and radiotherapy by modulating the immune system (91). The gene discussed is NLRP3; the disease is breast cancer.